Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sevuparin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Modus Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Modus Therapeutics Partners with Imperial College London on Malaria Drug
Details : Modus is currently developing sevuparin in sepsis/septic shock, and other conditions with systemic inflammation, with severe malaria being a further example. These conditions constitute major healthcare problems.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 06, 2021
Lead Product(s) : Sevuparin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Modus Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent. The findings come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care un...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Compass Pathways
Deal Size : Inapplicable
Deal Type : Inapplicable
Magic Mushroom Compound Performs as Well as Antidepressant in Small Study
Details : People treated with psilocybin – named ‘COMP360’ by its developers, showed marked improvements across a range of subjective measures, including in their ability to feel pleasure, and express emotions, greater reductions in anxiety and suicidal idea...
Product Name : COMP360
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Compass Pathways
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
World’s First Covid-19 Human Challenge Study Call for Volunteers
Details : The initial study will help scientists understand how the immune system reacts to coronavirus (the virus that causes Covid-19), and identify factors that influence how the virus is transmitted.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 17, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Enesi Pharma Limited
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will investigate the potential of combining Enesi's ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA technology and novel Polyplex DNA/RNA stabilisatio...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : RNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Enesi Pharma Limited
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the study, the patients, who were in multiple hospitals across Italy and Spain, had a 71 per cent reduced risk of dying compared to patients who had not taken the drug (baricitinib).
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imperial College Advances Covid-19 Vaccine into Next Phase
Details : Imperial College London in the UK has advanced its Covid-19 vaccine candidate into the next phase of the COVAC1 clinical trial following the success in the initial dose escalation phase involving 15 volunteers.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 20, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imperial College London Begins Dosing in Covid-19 Vaccine Study
Details : Based on a new self-amplifying RNA (saRNA) technology, the vaccine was found to be safe and generated promising evidence of an effective immune response in pre-clinical safety tests and animal studies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imperial to Begin First Human Trials of New COVID-19 Vaccine
Details : Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by Imperial College London. It will be the first test of a new self-amplifying RNA technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Self-Amplifying Rna Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Government of United Kingdom
Deal Size : $28.0 million
Deal Type : Funding
Imperial College London gets UK funding for Covid-19 vaccine
Details : The funding will fast-track Imperial’s development of an RNA vaccine against novel coronavirus.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 23, 2020
Lead Product(s) : Self-Amplifying Rna Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Government of United Kingdom
Deal Size : $28.0 million
Deal Type : Funding